- Home
- JPC vs LGND Comparison
JPC vs LGND Comparison
Compare JPC & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JPC
- LGND
- Stock Information
- Founded
- JPC 2003
- LGND 1987
- Country
- JPC United States
- LGND United States
- Employees
- JPC N/A
- LGND N/A
- Industry
- JPC Investment Managers
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- JPC Finance
- LGND Health Care
- Exchange
- JPC Nasdaq
- LGND Nasdaq
- Market Cap
- JPC 2.6B
- LGND 2.2B
- IPO Year
- JPC N/A
- LGND 1992
- Fundamental
- Price
- JPC $7.99
- LGND $120.67
- Analyst Decision
- JPC
- LGND Strong Buy
- Analyst Count
- JPC 0
- LGND 6
- Target Price
- JPC N/A
- LGND $145.00
- AVG Volume (30 Days)
- JPC 998.5K
- LGND 81.8K
- Earning Date
- JPC 01-01-0001
- LGND 02-27-2025
- Dividend Yield
- JPC 7.57%
- LGND N/A
- EPS Growth
- JPC N/A
- LGND 160.46
- EPS
- JPC N/A
- LGND 2.47
- Revenue
- JPC N/A
- LGND $152,422,000.00
- Revenue This Year
- JPC N/A
- LGND $26.86
- Revenue Next Year
- JPC N/A
- LGND $14.95
- P/E Ratio
- JPC N/A
- LGND $48.82
- Revenue Growth
- JPC N/A
- LGND N/A
- 52 Week Low
- JPC $5.94
- LGND $67.72
- 52 Week High
- JPC $7.36
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- JPC 48.71
- LGND 59.36
- Support Level
- JPC $7.97
- LGND $110.42
- Resistance Level
- JPC $8.04
- LGND $119.26
- Average True Range (ATR)
- JPC 0.05
- LGND 3.82
- MACD
- JPC -0.00
- LGND 0.61
- Stochastic Oscillator
- JPC 40.00
- LGND 81.35
About JPC Nuveen Preferred & Income Opportunities Fund
Nuveen Preferred & Income Opportunities Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. It invests its managed assets in preferred securities, and in other types of securities, primarily income-oriented securities such as corporate and taxable municipal debt and common equity.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.